Abstract
PGAM2 promotes resistance to enzalutamide by activating antiapoptotic BCL-xL and suppressing apoptosis, indicating that PGAM2 is a potential target for overcoming enzalutamide resistance in prostate cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have